Holen Sie sich die Stockscreener-App
171.34
1.13%
-1.96
Handel nachbörslich:
171.37
0.03
+0.02%
Überblick
Nachrichten
Preisverlauf
Optionskette
Warum fällt AZN?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$173.30
Offen:
$170.315
24-Stunden-Volumen:
2.26M
Relative Volume:
1.00
Marktkapitalisierung:
$265.73B
Einnahmen:
$60.48B
Nettoeinkommen (Verlust:
$10.40B
KGV:
51.46
EPS:
3.3297
Netto-Cashflow:
$8.05B
1W Leistung:
+1.82%
1M Leistung:
-10.27%
6M Leistung:
+84.69%
1J Leistung:
+123.71%
1-Tages-Spanne:
$169.85
$171.89
1-Wochen-Bereich:
$167.79
$175.03
52-Wochen-Spanne:
$72.89
$212.71
Astrazeneca Plc Stock (AZN) Company Profile
Compare AZN vs LLY, JNJ, ABBV, MRK, NVS
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
AZN
Astrazeneca Plc
|
171.34 | 263.09B | 60.48B | 10.40B | 8.05B | 3.3297 |
LLY
Lilly Eli Co
|
1,154.97 | 1.07T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
255.82 | 640.91B | 97.93B | 21.04B | 17.80B | 8.6278 |
ABBV
Abbvie Inc
|
257.41 | 453.91B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
129.79 | 322.95B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
158.44 | 296.72B | 54.66B | 13.58B | 16.05B | 7.0171 |
Astrazeneca Plc Stock (AZN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-27 | Eingeleitet | Citigroup | Buy |
| 2025-10-27 | Fortgesetzt | Jefferies | Buy |
| 2025-10-16 | Herabstufung | Deutsche Bank | Hold → Sell |
| 2025-04-15 | Eingeleitet | Exane BNP Paribas | Outperform |
| 2025-02-13 | Hochstufung | UBS | Neutral → Buy |
| 2025-02-12 | Eingeleitet | Morgan Stanley | Overweight |
| 2024-11-20 | Hochstufung | UBS | Sell → Neutral |
| 2024-11-06 | Hochstufung | Deutsche Bank | Sell → Hold |
| 2024-09-13 | Herabstufung | Deutsche Bank | Hold → Sell |
| 2024-05-30 | Eingeleitet | Goldman | Buy |
| 2024-04-16 | Hochstufung | Deutsche Bank | Sell → Hold |
| 2024-02-08 | Herabstufung | Deutsche Bank | Hold → Sell |
| 2024-01-23 | Eingeleitet | Morgan Stanley | Overweight |
| 2024-01-16 | Fortgesetzt | UBS | Sell |
| 2024-01-03 | Herabstufung | Jefferies | Buy → Hold |
| 2023-12-18 | Eingeleitet | HSBC Securities | Buy |
| 2023-09-25 | Hochstufung | Jefferies | Hold → Buy |
| 2023-07-14 | Eingeleitet | HSBC Securities | Buy |
| 2023-07-12 | Hochstufung | UBS | Neutral → Buy |
| 2023-07-05 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2023-04-11 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2023-01-05 | Eingeleitet | BMO Capital Markets | Outperform |
| 2022-09-15 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2022-09-07 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2022-08-29 | Hochstufung | Argus | Hold → Buy |
| 2022-06-14 | Herabstufung | UBS | Buy → Neutral |
| 2022-02-11 | Hochstufung | DZ Bank | Sell → Hold |
| 2021-12-07 | Herabstufung | Jefferies | Buy → Hold |
| 2021-08-12 | Fortgesetzt | JP Morgan | Overweight |
| 2021-04-12 | Herabstufung | Argus | Buy → Hold |
| 2021-03-16 | Hochstufung | Jefferies | Hold → Buy |
| 2021-02-25 | Hochstufung | UBS | Neutral → Buy |
| 2021-01-15 | Eingeleitet | Deutsche Bank | Buy |
| 2020-12-07 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2020-11-30 | Hochstufung | UBS | Sell → Neutral |
| 2020-11-11 | Hochstufung | HSBC Securities | Reduce → Hold |
| 2020-09-29 | Eingeleitet | Berenberg | Buy |
| 2019-11-22 | Eingeleitet | SVB Leerink | Outperform |
| 2019-10-25 | Hochstufung | Liberum | Hold → Buy |
| 2019-04-02 | Herabstufung | UBS | Neutral → Sell |
| 2019-02-05 | Eingeleitet | Exane BNP Paribas | Outperform |
| 2019-01-25 | Hochstufung | Shore Capital | Hold → Buy |
| 2018-12-11 | Fortgesetzt | Jefferies | Hold |
| 2018-10-09 | Eingeleitet | Guggenheim | Buy |
| 2018-08-16 | Herabstufung | Jefferies | Buy → Hold |
| 2018-03-19 | Hochstufung | Jefferies | Hold → Buy |
| 2018-02-06 | Bestätigt | Leerink Partners | Mkt Perform |
| 2018-02-05 | Bestätigt | Bernstein | Outperform |
| 2018-01-18 | Bestätigt | Leerink Partners | Mkt Perform |
| 2017-12-29 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2017-10-16 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2017-09-25 | Hochstufung | Exane BNP Paribas | Neutral → Outperform |
| 2017-09-22 | Hochstufung | Bernstein | Mkt Perform → Outperform |
Alle ansehen
Astrazeneca Plc Aktie (AZN) Neueste Nachrichten
Judge Dismisses AstraZeneca’s Bid To Stop Maine Pharmacy Law - Bloomberg Law News
AstraZeneca's drug pipeine is splitting opinion among City analysts - Proactive Investors
ASTRAZENECA : DZ Bank gives a Buy rating - marketscreener.com
ASTRAZENECA : Gets a Buy rating from Berenberg - marketscreener.com
ASTRAZENECA : Gets a Buy rating from Goldman Sachs - marketscreener.com
ASTRAZENECA : UBS remains its Buy rating - marketscreener.com
AstraZeneca reports Phase III results for Ultomiris and Sone-Ve - Clinical Trials Arena
AstraZeneca Stock: What We Thought of Earnings - Morningstar
AstraZeneca Kept at Buy as Berenberg Notes 'Upbeat' Q2 Earnings Call - marketscreener.com
AstraZeneca PLC (AZN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
AZN Q2 FY2026 earnings call - finance.biggo.com
AstraZeneca PLC (AZN) Stock Forecasts - Yahoo Finance
AstraZeneca PLC (AZN) Q2 2026 Earnings Call Highlights: Strong Oncology and Rare Disease Growth ... - Yahoo Finance
AZN Q2 Earnings and Sales Beat, Key Drugs Offset Generic Pressure - TradingView
AstraZeneca’s MONTEROSA Study Tracks Real World Outcomes for STRIDE in Liver Cancer - TipRanks
AstraZeneca: Q2 2026 Results Were All Right, But Farxiga Poses Risks (NYSE:AZN) - Seeking Alpha
AstraZeneca PLC (AZN) Investigation: Bronstein, Gewirtz & Grossma - The National Law Review
AstraZeneca rallies Monday, outperforms market - MarketWatch
AstraZeneca PLC (AZN) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
AstraZeneca quarterly net profit rises 2% on strong cancer drug sales - Yahoo Finance UK
Astrazeneca Rises on Profit Beat; Paramount Pauses WBD Deal | Stock Movers - marketscreener.com
AstraZeneca: In line Q2; correction of late is an entry point - marketscreener.com
Dow Jumps Over 400 Points; AstraZeneca Shares Rise After Q2 Earnings - Benzinga
AstraZeneca drug prices evolving in response to Trump policy, executive says - Reuters
AstraZeneca PLC Stock Analysis: Q2 Earnings Beat vs Bearish Trend - The Cryptonomist
Astrazeneca (AZN) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates - Yahoo Finance
AstraZeneca says adjusting drug pricing over Trump policies By Investing.com - Investing.com Nigeria
Astrazeneca Q2 Earnings Call Highlights - Yahoo Finance
What's Going on With AstraZeneca Stock Monday?AstraZeneca (NYSE:AZN) - Benzinga
AstraZeneca (NASDAQ: AZN) lifts H1 profit and backs 2026 outlook - Stock Titan
AstraZeneca oncology growth continues despite product setback - Investors' Chronicle
AstraZeneca profit rises on strong cancer drug sales - Yahoo Finance
AstraZeneca Sees 2030 Goal on Track as Cancer Drugs Drive Growth - WSJ
ASTRAZENECA : Jefferies gives a Buy rating - marketscreener.com
Bronstein, Gewirtz & Grossman, LLC Encourages AstraZeneca PLC (AZN) Shareholders to Inquire about Securities Investigation - ACCESS Newswire
Mixed Ultomiris HSCT-TMA results at AstraZeneca (NASDAQ: AZN) spur paediatric filings - Stock Titan
AstraZeneca PLC 2026 Q2ResultsEarnings Call Presentation (NYSE:AZN) 2026-07-27 - Seeking Alpha
AstraZeneca to Acquire Worldwide Rights to Lung Cancer Drug for $600M - Stock Titan
AstraZeneca sales boosted by soaring demand for cancer treatments - Yahoo Finance UK
AstraZeneca (NASDAQ: AZN) Phase III Sone-Ve data show gastric survival gain - Stock Titan
ASTRAZENECA PLC ORD SHS $0.25 (AZN.L) Q2 FY2026 earnings call transcript - Yahoo Finance
AstraZeneca stock edges up on earnings beat despite revenue miss - Investing.com
AstraZeneca Q2 Core Earnings, Revenue Rise; Interim Dividend Raised - marketscreener.com
AstraZeneca PLC Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
AstraZeneca reiterates guidance after topping Q2 profit expectations; shares up - Investing.com Nigeria
AstraZeneca PLC (AZN) Stock Analysis: Exploring a 26% Potential Upside and Strong Buy Ratings - DirectorsTalk Interviews
Market Open: Vodafone raises guidance, AstraZeneca H1 growth - Yahoo Finance UK
AstraZeneca CFO says AI is not expected to lead to job cuts - marketscreener.com
AstraZeneca sales rise as demand for cancer treatments grow - Yahoo Finance UK
AstraZeneca Logs Higher First-half Profit on Strong Oncology, Rare Disease Drugs Sales; Outlook Maintained - marketscreener.com
AstraZeneca’s Cancer Medicines Spur Profit Growth - Bloomberg
Finanzdaten der Astrazeneca Plc-Aktie (AZN)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.25%
0.06%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):